Discovery and development of a potent and highly selective WEE1 inhibitor IMP7068

被引：2
|
作者：
Cai, Sui Xiong
Ma, Ning
Wang, Xiaozhu
Jiang, Yangzhen
Zhang, Hongxia
Guo, Mingchuan
Zhou, Ruiyu
Tian, Ye Edward
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-3091
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3091
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Indicators of Response to the Wee1 Inhibitor Adavosertib in Acute Myeloid Leukemia
    Srivastava, Ankita
    Heckman, Caroline A.
    Miettinen, Juho Jalmari
    Harismendy, Olivier
    BLOOD, 2023, 142
  • [42] A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors
    Falchook, Gerald S.
    Sachdev, Jasgit
    Imedio, Esteban Rodrigo
    Kumar, Sanjeev
    Mugundu, Ganesh M.
    Jenkins, Suzanne
    Chmielecki, Juliann
    Jones, Suzanne
    Spigel, David R.
    Johnson, Melissa
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (03) : 493 - 502
  • [43] Discovery and development of BLU-285: A potent, highly selective inhibitor of KIT and PDGFRα activation loop mutants
    Hodous, Brian
    Evans, Erica
    Gardino, Alexandra
    Davis, Alison
    Zhu, Julia
    Wilson, Douglas
    Wilson, Kevin
    Dipietro, Lucian
    Kim, Joseph
    Brooijmans, Natasja
    Kadambi, Vivek
    Shutes, Adam
    Zhang, Yulian
    Kohl, Nancy
    Lengauer, Christoph
    Guzi, Timothy
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 253
  • [44] A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors
    Gerald S Falchook
    Jasgit Sachdev
    Esteban Rodrigo Imedio
    Sanjeev Kumar
    Ganesh M Mugundu
    Suzanne Jenkins
    Juliann Chmielecki
    Suzanne Jones
    David R Spigel
    Melissa Johnson
    Investigational New Drugs, 2023, 41 : 493 - 502
  • [45] A potent and highly selective sulfotransferase inhibitor
    Chapman, E
    Ding, S
    Schultz, PG
    Wong, CH
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2002, 124 (49) : 14524 - 14525
  • [46] Pharmacodynamic evaluation of pCDC2 and Wee1 signature as biomarkers of target engagement for the Wee1 tyrosine kinase inhibitor MK-1775
    Cheng, J. D.
    Tibes, R.
    Schellens, J. H.
    Shapiro, G. I.
    Pavlick, A. C.
    Oza, A. M.
    Xu, Y.
    Song, Y.
    Lam, R. L. H.
    Demuth, T.
    EJC SUPPLEMENTS, 2010, 8 (07): : 202 - 202
  • [47] Discovery of a potent and highly fluorescent sirtuin inhibitor
    Yoon, Y. K.
    Ali, M. A.
    Wei, A. C.
    Choon, T. S.
    Shirazi, A. N.
    Parang, K.
    MEDCHEMCOMM, 2015, 6 (10) : 1857 - 1863
  • [48] Discovery of a potent and selective Aurora kinase inhibitor
    Oslob, Johan D.
    Romanowski, Michael J.
    Allen, Darin A.
    Baskaran, Subramanian
    Bui, Minna
    Elling, Robert A.
    Flanagan, William M.
    Fung, Amy D.
    Hanan, Emily J.
    Harris, Shannon
    Heumann, Stacey A.
    Hoch, Ute
    Jacobs, Jeffrey W.
    Lam, Joni
    Lawrence, Chris E.
    McDowell, Robert S.
    Nannini, Michelle A.
    Shen, Wang
    Silverman, Jeffrey A.
    Sopko, Michelle M.
    Tangonan, Bradley T.
    Teague, Juli
    Yoburn, Josh C.
    Yu, Chul H.
    Zhong, Min
    Zimmerman, Kristin M.
    O'Brien, Tom
    Lew, Willard
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (17) : 4880 - 4884
  • [49] Discovery of WS-157 as a highly potent,selective and orally active EGFR inhibitor
    Pengxing He
    Shenghui Niu
    Shuai Wang
    Xiaojing Shi
    Siqi Feng
    Linna Du
    Xuyang Zhang
    Zhilu Ma
    Bin Yu
    Hongmin Liu
    ActaPharmaceuticaSinicaB, 2019, 9 (06) : 1193 - 1203
  • [50] Discovery and preclinical evaluation of a novel highly selective and potent CDK12 inhibitor
    Yamakawa, Hiroko
    Mizutani, Akio
    Arikawa, Yasuyoshi
    Ebara, Shunsuke
    Satoh, Yoshihiko
    Morishita, Daisuke
    CANCER SCIENCE, 2023, 114 : 831 - 831
12345